Compare Enveric Biosciences Inc (ENVB) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lockheed Martin Corporation — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Lockheed Martin Corporation trades at $514.83 (market cap $118.62B). The key difference: Lockheed Martin Corporation is far larger — about 22297× Enveric Biosciences Inc's market cap, and Lockheed Martin Corporation pays a 2.68% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | LMT | |
|---|---|---|
Market Cap | $5.32M | $118.62B |
Sector | Health | Industrials |
52-Week High | $17.40 | $676.70 |
52-Week Low | $1.28 | $410.74 |
Enterprise Value | $408.82K | $137.42B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Lockheed Martin (LMT) trades at $515.75, up 0.15% on the day, with a bearish technical signal but strong analyst support. The stock shows robust fundamentals including a $75.05B revenue in 2025, a 6.38% net income margin, and a high ROE of 67.64%. Recent news highlights expansion into European venture capital and a $194B backlog, signaling long-term demand. However, earnings misses in Q4 2025 and Q1 2026 pose near-term execution challenges amid escalating defense spending trends.
The outlook for LMT is positive due to strong defense budgets and a massive backlog, but risks include earnings volatility and high debt levels. With 57% of analysts rating it Buy and a consensus price target of $614, the stock offers potential upside, though investors should monitor margin improvements and geopolitical developments affecting defense contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
